Medtronic, Inc. (MDT) revealed pivotal data for the Medtronic Arctic Front CryoAblation Catheter System would be presented as a late breaking clinical trial at the 59th Annual Scientific Session of the American College of Cardiology on March 15.
The STOP-AF, or Sustained Treatment of Paroxysmal Atrial Fibrillation, clinical trial is evaluating the safety and efficacy of the Arctic Front CryoAblation Catheter System for paroxysmal atrial fibrillation patients. The system is approved for use in Europe, Australia and Hong Kong and is under investigational use in the United States.
Additionally, data from the Medtronic-sponsored CONNECT, or Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision, clinical trial also would be presented as a late breaker on March 15. The trial is assessing how the use of the Medtronic CareLink Network to remotely monitor patients with Medtronic cardiac resynchronization therapy-defibrillators and implantable cardioverter-defibrillators equipped with Conexus Wireless Telemetry might effectively enable better patient care and reduce unnecessary healthcare costs.
For comments and feedback: editorial@rttnews.com